Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
about
Randomized double-blind trial of prophylactic topical Evozac(®) Calming Skin Spray for gefitinib-associated acne-like eruption.Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case reportPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisInvolvement of substance P and the NK-1 receptor in human pathology.Aprepitant and fosaprepitant: a 10-year review of efficacy and safetySubstance P in heart failure: the good and the bad.Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literatureSafety of neurokinin-1 receptor antagonists.Investigational drugs for pruritus.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.Cutaneous Complications of Targeted Melanoma Therapy.[New treatment options for chronic pruritus].Substance P activates Mas-related G protein-coupled receptors to induce itch.Treatment for Refractory Pruritus Using Oral Aprepitant.Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour.Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.Management of Dermatologic Toxicities Associated With Targeted Therapy.Aprepitant for the Treatment of Chronic Refractory Pruritus.RTL1 promotes melanoma proliferation by regulating Wnt/β-catenin signalling.[Cutaneous side effects of targeted cancer drugs].Efficient biocatalytic synthesis of (R)-[3,5-bis(trifluoromethyl)phenyl] ethanol by a newly isolated Trichoderma asperellum ZJPH0810 using dual cosubstrate: ethanol and glycerol.
P2860
Q33895537-C60B930F-63A7-4948-83CA-59C414C3D65DQ34219848-24B0332D-2D0E-49AC-911E-188C09426A53Q34272887-282DA5D0-9AB2-42EF-8AF2-283C9CE7414BQ34413850-F876DE03-9FDA-492E-8E88-BB60D836D5C5Q35345557-86CCAABC-D1FC-4C11-B497-74F2072024C5Q35670008-2F801330-58DB-4980-98F5-9815CD60FAB8Q36311246-0187981A-19BB-47A8-AA5C-49EB67103841Q38109245-0FD06928-A289-4573-9DB2-B1F1A9360327Q38118383-97EAC5D9-CA07-46C2-A9B6-4B68602A7C7FQ38201503-2E2485D2-18D0-407D-8FB1-1CB1A8F8FAC9Q38217456-B9FB2D01-CCA2-4C20-8528-F3C330EB8394Q38255717-024D49BB-06EE-41DA-AAD3-72C8F3213C56Q38958844-50F0C22E-8CC6-406F-9366-4E08217BA686Q40633979-5AC2AB9C-5178-4005-A189-F8C879E4AF40Q41285293-40F32648-3FC8-482C-90FA-8D8AE92094BEQ42087756-FB5DBFDF-AC7D-447E-9D3A-42EFBF740AD8Q43908243-76E7CFB4-4282-42B8-9B99-A4B1307A89D6Q44849246-8C0FC0FF-59C6-4826-BE31-6C9D444BB7FBQ46896984-3CC4CA32-2452-46C7-9CC6-6B7A84C62313Q47141491-7F788C31-816E-4E12-B08F-C94033B83A64Q47891968-33A79D6D-8DAE-4A65-80B9-6134A5536C46Q53193539-8EF7F336-5C1E-46E1-89B9-886FC54F40D4Q53737159-A978C654-0323-4668-8B5D-55773360E4B6
P2860
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Aprepitant for management of s ...... cer treatments: a pilot study.
@en
Aprepitant for management of s ...... cer treatments: a pilot study.
@nl
type
label
Aprepitant for management of s ...... cer treatments: a pilot study.
@en
Aprepitant for management of s ...... cer treatments: a pilot study.
@nl
prefLabel
Aprepitant for management of s ...... cer treatments: a pilot study.
@en
Aprepitant for management of s ...... cer treatments: a pilot study.
@nl
P2093
P50
P1433
P1476
Aprepitant for management of s ...... cer treatments: a pilot study.
@en
P2093
Francesco M Guida
Gaia Schiavon
Marco Imperatori
Olga Venditti
Pierpaolo Berti
P304
P356
10.1016/S1470-2045(12)70373-X
P577
2012-09-18T00:00:00Z